Investigated Drug Usage Anticancer Therapy Study Design Result Reference urea+lactic acid prophylactic capecitabine randomized, placebo- controlled no difference between the study arms Wolf et al. J ClinOncol. 2010 pyridoxine (vitamine B6) prophylactic capecitabine randomized, placebo- controlled no difference between the study arms Kang et al. J ClinOncol. 2010 meta-analysis no difference between the study arms Zhou et al. Biomed Rep. 2013 randomized, placebo- controlled no difference between the study arms Braik et al. J Community Support Oncol. 2014 meta-analysis no difference between the study arms Jo et al. ClinExp Dermatol. 2015 Mapisal ® prophylactic pegylated liposomal doxorubicin observational study, one armed no HFSR under Mapisal® Lademann et al. Skin Pharmacol Physiol. 2014 therapeutic diverse usage of Mapisal if HFSR grade II or III occured reduction of HFSR grade under Mapisal® Lademann et al. Skin Pharmacol Physiol. 2014 Mapisal® vs. urea prophylactic capecitabine randomized, controlled superiority of urea Hofheinz&Gencer et al. J ClinOncol. 2015 urea prophylactic sorafenib randomized, placebo- controlled superiority of urea Ren et al. J ClinOncol. 2015 urea vs. ceramide / hydrocolloid therapeutic sorafenib randomized, controlled less worsening of HFSR under hydrocolloid Shinohara et al. Ann Oncol. 2014 aluminium chlorohydrate (antiperspirant) prophylactic pegylated liposomal doxorubicin randomized, placebo-controlled less grade II / III HFSR under antiperspirant Templeton et al. Breast. 2014 celecoxib prophylactic capecitabine / xelox randomized, four armed less grade > I HFSR under celecoxib Zhang et al.  J Cancer Res ClinOncol. 2011 prophylactic capecitabine randomized, prospective less any grade HFSR under celecoxib Zhang et al. Ann Oncol. 2012

Table 1: Selection of studies investigating prophylactic or therapeutic strategies against HFSR.